Key result
Renal denervation reduced ventricular arrhythmias by 3.53 events/patient/month (95% CI -5.48 to -1.57) and overall ICD therapies by 2.68 events/patient/month in patients with refractory VAs.
Why the study?
Ventricular arrhythmias are a major cause of morbidity and mortality in heart disease, and recent studies had begun evaluating the effect of renal denervation on their occurrence.
Does renal denervation reduce the occurrence of ventricular arrhythmias and ICD therapies in patients with refractory ventricular arrhythmias?
Meta-Analysis (n=152)
Does renal denervation reduce the occurrence of ventricular arrhythmias and ICD therapies in patients with refractory ventricular arrhythmias?
Renal denervation appears to be a safe and effective adjunctive therapy for reducing ventricular arrhythmias and ICD therapies in patients with refractory VAs.
INTRODUCTION: Ventricular arrhythmias (VAs) are a major cause of morbidity and mortality in patients with heart disease. Recent studies evaluated the effect of renal denervation (RDN) on the occurrence of VAs. We conducted a systematic review and meta-analysis to determine the efficacy and safety of this procedure. METHODS AND RESULTS: A systematic search of the literature was performed to identify studies that evaluated the use of RDN for the management of VAs. Primary outcomes were reduction in the number of VAs and implantable cardioverter-defibrillator (ICD) therapies. Secondary outcomes were changes in blood pressure and renal function. Ten studies (152 patients) were included in the meta-analysis. RDN was associated with a reduction in the number of VAs, antitachycardia pacing, ICD shocks, and overall ICD therapies of 3.53 events/patient/month (95% confidence interval [CI] = -5.48 to -1.57), 2.86 events/patient/month (95% CI = -4.09 to -1.63), 2.04 events/patient/month (95% CI = -2.12 to -1.97), and 2.68 events/patient/month (95% CI = -3.58 to -1.78), respectively. Periprocedural adverse events occurred in 1.23% of patients and no significant changes were seen in blood pressure or renal function. CONCLUSIONS: In patients with refractory VAs, RDN was associated with a reduction in the number of VAs and ICD therapies, and was shown to be a safe procedure.
No takes yet. Share an insight, caveat, or question.
Prado et al. (2021) conducted a meta-analysis in Ventricular arrhythmias (n=152). Renal denervation was evaluated on Reduction in the number of VAs and implantable cardioverter-defibrillator (ICD) therapies (MD -3.53 events/patient/month, 95% CI -5.48 to -1.57). Renal denervation reduced ventricular arrhythmias by 3.53 events/patient/month (95% CI -5.48 to -1.57) and overall ICD therapies by 2.68 events/patient/month in patients with refractory VAs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: